Management ChangeJul 7, 2026, 08:57 AM
Akari Therapeutics Appoints Patricia LoRusso to Scientific Advisory Board
AI Summary
Akari Therapeutics, Plc announced the appointment of Patricia LoRusso, D.O. to its Scientific Advisory Board. Dr. LoRusso is a globally recognized leader in early-phase oncology clinical development with over 25 years of experience, including serving as past President of AACR. Her strategic and clinical insights are expected to be instrumental as Akari advances its novel RNA splicing modulator payload ADC, AKTX-101, into a Phase 1 First-in-Human trial targeted for mid-2027.
Key Highlights
- Akari Therapeutics appointed Patricia LoRusso, D.O. to its Scientific Advisory Board.
- Dr. LoRusso brings over 25 years of experience in medical oncology and early-phase clinical trials.
- She currently serves as Amy and Joseph Perella Professor of Medicine at Yale Cancer Center.
- Dr. LoRusso is a past President of the American Association for Cancer Research (AACR).
- Her expertise will support the advancement of Akari's lead program, AKTX-101, into Phase 1 trials.
- AKTX-101, a TROP2-targeting ADC, is expected to begin its First-in-Human trial by mid-2027.
- Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5.
Price Impact
More from AKTX